Kisqali emerges as a blockbuster of Novartis AG (NVS) with record Q2 growth
Recently released The most underrated pharma stock to buy now. Novartis AG stands third among the most underrated stocks.
Novartis AG (NYSE: NVS) is a Swiss pharmaceutical leader focused on developing innovative therapies across oncology, immunology, neuroscience, cardiovascular and renal diseases. The company continues to invest heavily in research and development with the aim of providing groundbreaking drugs that improve patient outcomes around the world.
The company’s Kisqali (Ribociclib) has emerged as a major growth driver, with 64% of its second quarter sales worldwide and 100% in the US targeting metastatic breast cancer, making it a potential blockbuster. Other notable therapies include Pluvicto for prostate cancer and Scemblix for chronic myeloid leukemia, both of which show strong commercial momentum.
The Novartis AG (NYSE: NVS) is expanding the existence of nephrology. Vanrafia (Atrasentan) recently marked significant advances with FDA accelerated approval to reduce proteinuria in IgA nephropathy. Fabhalta (Iptacopan), an oral treatment for C3 glomerular disorders, has also been approved. Ongoing trials include Zigakibart, IGAN’s Phase III candidate, with results expected in 2026.
The business has introduced Coartem Baby, a pediatric malaria treatment approved by Swiss Medic. Addresses unmet needs of infants under 5 kg. Novartis AG (NYSE: NVS) is planning to launch it on a non-commercial basis in endemic malaria regions.
Laboratory pharmacy technician preparing medicines for retail distribution.
The company has streamlined the pipeline around the core treatment sector, where several phase III trials are underway. These include lembritinib for autoimmune disease, iaanalumab for lupus, and YTB323 for neuroimmune disorders. The company expects 15 submissionable data leadouts over the next two years, highlighting a robust late pipeline.
Although we acknowledge the potential of NVS as an investment, we believe certain AI stocks offer greater promotion opportunities and pose a risk of decline. If you’re looking for a highly undervalued AI stock that can make a significant profit from the tariff and supervision trends of the Trump era, check out our free report. Best Short-Term AI Stocks.
Read next: 30 stocks that double in three years and 11 Hidden AI Strains Buy Now.
Disclosure: None.